^
Association details:
| Biomarker: | FLT3 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + azacitidine (DNA methylation inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 Mutations
Published date:
11/05/2020
Excerpt:
Ven+Aza compared to Aza monotherapy resulted in significantly higher CR+CRh rates among treatment-naïve pts with FLT3mut ineligible for intensive chemotherapy.
DOI:
10.1182/blood-2020-134100
Trial ID:
